BeiGene, Ltd. (BGNE) Stock Rating Reaffirmed by Cowen and Company
BeiGene, Ltd. (NASDAQ:BGNE)‘s stock had its “buy” rating reissued by investment analysts at Cowen and Company in a research note issued to investors on Tuesday.
The analysts wrote, “SGMO reported 3Q17 results and is on track to report first data from the Ph1/2 trials.””
Other analysts also recently issued reports about the company. Robert W. Baird reiterated a “neutral” rating and set a $83.00 target price (up from $58.00) on shares of BeiGene in a research note on Tuesday. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $86.00 price target (up from $43.00) on shares of BeiGene in a research note on Tuesday, August 15th. Zacks Investment Research downgraded BeiGene from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Ladenburg Thalmann Financial Services started coverage on BeiGene in a research note on Monday, August 7th. They issued a “buy” rating and a $81.00 price target on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $95.00 price target (up from $87.00) on shares of BeiGene in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $96.67.
BeiGene (NASDAQ:BGNE) last issued its earnings results on Monday, November 13th. The company reported $2.54 EPS for the quarter, beating the consensus estimate of $0.23 by $2.31. The business had revenue of $220.21 million for the quarter, compared to analysts’ expectations of $1.55 million. During the same quarter in the prior year, the business posted ($1.08) earnings per share. equities research analysts expect that BeiGene will post -5.12 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “BeiGene, Ltd. (BGNE) Stock Rating Reaffirmed by Cowen and Company” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/14/beigene-ltd-bgne-stock-rating-reaffirmed-by-cowen-and-company.html.
A number of institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC bought a new position in BeiGene in the 3rd quarter worth $590,000. Orbimed Advisors LLC raised its holdings in BeiGene by 2.0% in the 3rd quarter. Orbimed Advisors LLC now owns 1,313,788 shares of the company’s stock worth $135,925,000 after purchasing an additional 26,200 shares during the period. Janus Henderson Group PLC bought a new position in BeiGene in the 3rd quarter worth $33,744,000. Jane Street Group LLC bought a new position in BeiGene in the 3rd quarter worth $339,000. Finally, Vident Investment Advisory LLC raised its holdings in BeiGene by 2.6% in the 3rd quarter. Vident Investment Advisory LLC now owns 29,191 shares of the company’s stock worth $3,020,000 after purchasing an additional 733 shares during the period. 52.09% of the stock is currently owned by institutional investors.
BeiGene Company Profile
BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.
Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.